1468 related articles for article (PubMed ID: 30736840)
41. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
[TBL] [Abstract][Full Text] [Related]
42. SPAG5 promotes proliferation and suppresses apoptosis in bladder urothelial carcinoma by upregulating Wnt3 via activating the AKT/mTOR pathway and predicts poorer survival.
Liu JY; Zeng QH; Cao PG; Xie D; Yang F; He LY; Dai YB; Li JJ; Liu XM; Zeng HL; Fan XJ; Liu L; Zhu YX; Gong L; Cheng Y; Zhou JD; Hu J; Bo H; Xu ZZ; Cao K
Oncogene; 2018 Jul; 37(29):3937-3952. PubMed ID: 29662193
[TBL] [Abstract][Full Text] [Related]
43. Up-regulated lncRNA GAS5 promotes chemosensitivity and apoptosis of triple-negative breast cancer cells.
Li J; Li L; Yuan H; Huang XW; Xiang T; Dai S
Cell Cycle; 2019 Aug; 18(16):1965-1975. PubMed ID: 31282278
[TBL] [Abstract][Full Text] [Related]
44. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
45. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
46. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.
Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W
Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785
[TBL] [Abstract][Full Text] [Related]
47. BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression.
Li Y; Wang Y; Zhang W; Wang X; Chen L; Wang S
Sci Rep; 2021 Feb; 11(1):4774. PubMed ID: 33637776
[TBL] [Abstract][Full Text] [Related]
48. Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer.
Ha DH; Min A; Kim S; Jang H; Kim SH; Kim HJ; Ryu HS; Ku JL; Lee KH; Im SA
Sci Rep; 2020 Jun; 10(1):9930. PubMed ID: 32555285
[TBL] [Abstract][Full Text] [Related]
49. Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications.
Iqbal MA; Chattopadhyay S; Siddiqui FA; Ur Rehman A; Siddiqui S; Prakasam G; Khan A; Sultana S; Bamezai RN
FEBS J; 2021 Jan; 288(2):471-485. PubMed ID: 32356386
[TBL] [Abstract][Full Text] [Related]
50. NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer.
Zhou L; Wang D; Sheng D; Xu J; Chen W; Qin Y; Du R; Yang X; He X; Xie N; Liu S; Zhang L
Theranostics; 2020; 10(5):2405-2421. PubMed ID: 32104513
[No Abstract] [Full Text] [Related]
51. Potentiation of cancerous progression by LISCH7 via direct stimulation of TGFB1 transcription in triple-negative breast cancer.
Tang X; Zhou Y; Liu Y; Zhang W; Liu C; Yan C
J Cell Biochem; 2020 Nov; 121(11):4642-4653. PubMed ID: 32048750
[TBL] [Abstract][Full Text] [Related]
52. Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer.
Li Q; Jin W; Cai Y; Yang F; Chen E; Ye D; Wang Q; Guan X
Biochem Biophys Res Commun; 2017 Apr; 485(3):693-697. PubMed ID: 28237701
[TBL] [Abstract][Full Text] [Related]
53. The circRNA circIFI30 promotes progression of triple-negative breast cancer and correlates with prognosis.
Xing L; Yang R; Wang X; Zheng X; Yang X; Zhang L; Jiang R; Ren G; Chen J
Aging (Albany NY); 2020 Jun; 12(11):10983-11003. PubMed ID: 32497020
[TBL] [Abstract][Full Text] [Related]
54. Profilin 2 (PFN2) promotes the proliferation, migration, invasion and epithelial-to-mesenchymal transition of triple negative breast cancer cells.
Ling Y; Cao Q; Liu Y; Zhao J; Zhao Y; Li K; Chen Z; Du X; Huo X; Kang H; Chen Z
Breast Cancer; 2021 Mar; 28(2):368-378. PubMed ID: 33047272
[TBL] [Abstract][Full Text] [Related]
55. PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.
Brasó-Maristany F; Filosto S; Catchpole S; Marlow R; Quist J; Francesch-Domenech E; Plumb DA; Zakka L; Gazinska P; Liccardi G; Meier P; Gris-Oliver A; Cheang MC; Perdrix-Rosell A; Shafat M; Noël E; Patel N; McEachern K; Scaltriti M; Castel P; Noor F; Buus R; Mathew S; Watkins J; Serra V; Marra P; Grigoriadis A; Tutt AN
Nat Med; 2016 Nov; 22(11):1303-1313. PubMed ID: 27775704
[TBL] [Abstract][Full Text] [Related]
56. Actin-like protein 6A/MYC/CDK2 axis confers high proliferative activity in triple-negative breast cancer.
Jian Y; Huang X; Fang L; Wang M; Liu Q; Xu H; Kong L; Chen X; Ouyang Y; Wang X; Wei W; Song L
J Exp Clin Cancer Res; 2021 Feb; 40(1):56. PubMed ID: 33541412
[TBL] [Abstract][Full Text] [Related]
57. miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
Li J; Lai Y; Ma J; Liu Y; Bi J; Zhang L; Chen L; Yao C; Lv W; Chang G; Wang S; Ouyang M; Wang W
BMC Cancer; 2017 Nov; 17(1):745. PubMed ID: 29126392
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.
Camarda R; Zhou AY; Kohnz RA; Balakrishnan S; Mahieu C; Anderton B; Eyob H; Kajimura S; Tward A; Krings G; Nomura DK; Goga A
Nat Med; 2016 Apr; 22(4):427-32. PubMed ID: 26950360
[TBL] [Abstract][Full Text] [Related]
59. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.
Chen B; Wang J; Dai D; Zhou Q; Guo X; Tian Z; Huang X; Yang L; Tang H; Xie X
J Exp Clin Cancer Res; 2017 May; 36(1):65. PubMed ID: 28494797
[TBL] [Abstract][Full Text] [Related]
60. New substituted quinoxalines inhibit triple-negative breast cancer by specifically downregulating the c-MYC transcription.
Hu MH; Wu TY; Huang Q; Jin G
Nucleic Acids Res; 2019 Nov; 47(20):10529-10542. PubMed ID: 31584090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
